Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page
- CheckyesterdayChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedThe revision label was updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. No changes to study content or eligibility criteria are indicated.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded a 'Show glossary' option, introduced the label 'Last Update Submitted that Met QC Criteria' (changing from 'Last Update Submitted that met QC Criteria'), and adjusted capitalization for 'No FEAR Act Data'. The site revision was updated from v3.3.4 to v3.4.0; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check51 days agoChange DetectedAdministrative updates to the study page include new 2026 update dates and the removal of an older regulatory note; these are updates to page metadata rather than the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check58 days agoChange DetectedMinor update: revision label changed from v3.3.3 to v3.3.4; no study content or functionality was changed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.